What was the dollar value of contract HHSO100201700020C?

The total obligated amount for contract HHSO100201700020C is $279,610,568.

When was contract HHSO100201700020C awarded?

Contract HHSO100201700020C was first awarded on September 21, 2017.

What NAICS code does contract HHSO100201700020C fall under?

Contract HHSO100201700020C is classified under NAICS code 541711.

What agency awarded contract HHSO100201700020C?

Contract HHSO100201700020C was awarded by Department Of Health And Human Services.

Contract HHSO100201700020C

Name: Contract HHSO100201700020C — federal award record
Creator: BesaGov
License: https://www.usa.gov/government-works

Regeneron Pharmaceuticals Inc · Department Of Health And Human Services · September 21, 2017

Cost SharingFull & Open CompetitionNAICS 541711

Regeneron Pharmaceuticals Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 21, 2017 for $279.61 million of work in research and development in biotechnology. Performance is in Tarrytown, NY. It was awarded under full and open competition. The contract has been modified 16 times since the base award It uses cost sharing contract pricing. The most recent modification was on August 8, 2025.

Obligated to date

$279.61M

$279,610,568

Current value

$279.61M

Potential value

$360.38M

if all options exercised

Modifications

Latest August 8, 2025

Contract details

PIID: HHSO100201700020C
Award type: Definitive Contract
Pricing: Cost Sharing
Set-aside: No Set Aside Used.
Competition: Full And Open Competition
NAICS: 541711 · Research And Development In Biotechnology
Product / service: Health R&D Services; Health Care Services; Experimental Development
Place of performance: Tarrytown, NY
First action: September 21, 2017
Latest action: August 8, 2025

Description

E.O. RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING. DESCOPE MOD IAW WITH RTWS TO REMOVE UNUSED FUNDS FROM MULTIPLE CLINS RESULTING IN A DE-OBLIGATION OF $331,708,160.10 AND A REDUCTION IN TOTAL CONTRAC

Modification timeline

August 8, 2025

Mod P00016
E.O. RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING. DESCOPE MOD IAW WITH RTWS TO REMOVE UNUSED FUNDS FROM MULTIPLE CLINS RESULTING IN A DE-OBLIGATION OF $331,708

$-331.71M
December 5, 2024

Mod P00015
NO COST MODIFICATION TO REVISE THE JOINT OVERSIGHT COMMITTEE MEMBERS AND EXTEND THE PERIOD OF PERFORMANCE FOR CLIN 0001 TO SEPT 25, 2027.

$0
December 14, 2023

Mod P00014
BILATERAL MODIFICATION TO UPDATE THE CONTRACT WRITING SYSTEM FOR AN IPP ERROR.

$0
November 13, 2023

Mod P00013
NO COST MODIFICATION TO REVISE THE AGREEMENTS OFFICER.

$0
August 21, 2023

Mod P00012
(1) REVISE PERIOD OF PERFORMANCE, (2) ADD CLIN 0007 COV2-NEXT GEN, STATEMENT OF WORK, (3) OBLIGATED: $326,475,498.00, AND (4) ADD PROHIBITION ON A BYTEDANCE COV

$326.48M

June 30, 2022

Mod P00011
THE PURPOSE OF THIS MODIFICATION IS TO: (1) EXTEND THE PERIOD OF PERFORMANCE

$0
May 28, 2021

Mod P00010
THE PURPOSE OF THIS MODIFICATION IS TO: (1) EXTEND THE PERIOD OF PERFORMANCE FOR THE BASE (CLIN 0001) TO SEPTEMBER 30, 2023 AND OPTION 2 (CLIN 0003) TO SEPTEMBE

$0
June 18, 2020

Mod P00009
ADDED A SUPPLEMENT FOR KEVZARA. THIS COVERS THE OVER-RECRUITMENT OF 1,470 PARTICIPANTS.

$53.52M
June 15, 2020

Mod P00008
REGENERON OTHER TRANSACTION AUTHORITY (OTA) AWARD

$85.09M
April 29, 2020

Mod P00007
REGENERON OTHER TRANSACTION AUTHORITY (OTA) AWARD

$9.25M

Similar contracts

Recipient	Agency	Date	Obligated
University Of Illinois	Department Of Health And Human Services	March 26, 2026	$2.27M
Battelle Memorial Institute	Department Of Health And Human Services	March 25, 2026	$9.65M
University Of Texas Medical Branch At Galveston	Department Of Health And Human Services	March 23, 2026	$1.61M
Regeneron Pharmaceuticals Inc	Department Of Health And Human Services	March 19, 2026	$8.60M
Battelle Memorial Institute	Department Of Health And Human Services	March 17, 2026	$2.23M
Battelle Memorial Institute	Department Of Health And Human Services	March 17, 2026	$2.22M

Top contractors in NAICS 541711

Lifetime obligated dollars across all federal contracts in this NAICS code.

#	Contractor	Contracts	Obligated
1	Alliance For Energy Innovation, Llc	2	$10.68B
2	Emergent Product Development Gaithersburg Inc.	7	$1.63B
3	Janssen Pharmaceuticals, Inc.	2	$1.05B
4	Regeneron Pharmaceuticals Inc	4	$1.01B
5	Siga Technologies, Inc.	3	$560.59M
6	Battelle National Biodefense Institute, Llc	106	$469.31M
7	Glaxosmithkline, Llc	6	$321.65M
8	Merck Sharp & Dohme Llc	3	$309.72M
9	Sri International	130	$258.61M
10	American Type Culture Collection	7	$243.18M

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

Helpful guides

Continue learning

See all guides →

Keep researching

Frequently asked questions

What is contract HHSO100201700020C?

Contract HHSO100201700020C is a federal contract awarded to Regeneron Pharmaceuticals Inc by Department Of Health And Human Services on September 21, 2017 for $279.61 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY. It has been modified 16 times since the base award.

Who won contract HHSO100201700020C?

Regeneron Pharmaceuticals Inc won contract HHSO100201700020C from Department Of Health And Human Services.

How much is contract HHSO100201700020C worth?

Contract HHSO100201700020C has obligated $279.61 million to date, with a total potential value of $360.38 million if all options are exercised.